Incisional Negative Pressure Dressing on Clean Closed Groin Incisions

NCT ID: NCT02006511

Last Updated: 2023-05-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2013-12-01

Study Completion Date

2014-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Wound complications associated with surgical incisions range from minor to life threatening. Surgical site infections occurring usually occur within 30 days and are one of the most common surgical complications. Perigraft infections in groin wounds can be devastating. Even superficial wounds can progress to deep wounds resulting in graft infection, need for explantation, and sepsis or amputation requirement. Negative pressure wound therapy has had favorable results on closed wounds in trauma populations. Similarly, negative pressure wound therapy has had positive benefits in closed incisions such as sternal wounds following cardiac surgery. As a result, the PrevenaTM Incision Management System(IMS) was developed to allow easier application of negative pressure therapy to closed wounds. Application of the PrevenaTM IMS dressing would portend the aforementioned benefits of Vacuum Assisted Closure (VAC®) therapy with the added benefits of protecting the wound from contamination and bolstering the wound edges for better approximation and consequently better aesthetic outcome. However, no comparison between negative pressure therapy as a dressing and standard wound dressings exists.

The purpose of this study is to assess the efficacy and safety of topical negative pressure therapy application with Prevena™ versus standard of care wound therapy on closed groin incisions in high risk patients undergoing vascular surgery.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Complication of Surgical Procedure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Incisional Neg Pressure Wound Therapy

Incisional negative pressure wound therapy dressings applied to the surgical site

Group Type EXPERIMENTAL

Incisional Neg Pressure Wound Therapy (Prevena™)

Intervention Type DEVICE

Negative pressure wound therapy dressing applied over closed surgical incision

Standard of care wound dressing

Standard of care wound dressing of gauze and tape or the equivalent applied to the surgical site

Group Type ACTIVE_COMPARATOR

Standard of Care wound therapy

Intervention Type OTHER

Gauze type dressing.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Incisional Neg Pressure Wound Therapy (Prevena™)

Negative pressure wound therapy dressing applied over closed surgical incision

Intervention Type DEVICE

Standard of Care wound therapy

Gauze type dressing.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female 18 years of age or greater
* Scheduled elective vascular surgery which requires groin incision. Elective surgery is defined as planned surgery a minimum of 24 hours before the procedure.
* Meets high risk criteria according to the following rating system
* Scores at least 8 points for the following risk factors:

• MAJOR 4 points:
* BMI of \<18 kg/m2 or ≥BMI 40 kg/m2 \*\*\*
* Insulin dependent Diabetes Mellitus\*
* Dialysis (hemodialysis or peritoneal dialysis)\*\*

• INTERMEDIATE 2 points:
* Previous groin surgery
* Diabetes Mellitus not requiring insulin\*
* Chronic lung disease GOLD \>2
* On long-term immunosuppressive medication (\>3 months at time of enrollment)
* Chronic kidney disease (defined as a GFR \<30ml/min/1.73m2 for 3 months)\*\*
* Previous lower extremity or abdominal wall radiotherapy radiotherapy
* BMI between 35 and 40\*\*\*

• MINOR 1 point:
* Previous abdominal surgery
* Peripheral vascular disease
* Female gender
* Age \>75 years old
* Hospitalized at least 7 days before surgery

\*, \*\*, \*\*\* mutually exclusive, highest score should be used
* Capable of providing informed consent or has a legally authorized representative (LAR) if unable to provide informed consent
* Willing and able to adhere to the study visit schedule

Exclusion Criteria

* Subjects meeting any of the following criteria may not be enrolled in the study:
* Is pregnant
* Has a systemic infection at the time of surgery (ie bacteremia)
* Has a remote body site infection at the time of surgery (ie UTI)
* Has a known allergy or hypersensitivity to silver, adhesive, or dressing material
* Has a requirement for competing therapy (ie open negative pressure wound therapy)
* Is simultaneously participating in another interventional trial
Minimum Eligible Age

18 Years

Maximum Eligible Age

120 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Maryland, Baltimore

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Rachel Bluebond-Langer, MD

Role: PRINCIPAL_INVESTIGATOR

University of Maryland, School of Medicine, Dept of Surgery, Division of Plastic Surgery

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Maryland Medical Center

Baltimore, Maryland, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HP-00057511

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Regenn® Therapy System Safety Study
NCT06259409 RECRUITING PHASE1